<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

 

 

Prostate Cancer PDX Models
A Champions Model Cohort

A robust cohort of rare and meticulously curated Prostate Cancer PDX Models directly established from primary, metastatic, and pretreated patient tumors to support your prostate cancer drug development research.

 

 

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

 

Prostate Cancer PDX Models Cohort to support Prostate Cancer Research

Champions Oncology offers 15* clinically relevant Prostate Cancer PDX models, derived from primary and metastatic tumors, many of which originated from patients pretreated with Standard of Care therapies. Thirteen models have been characterized through Next Generation Sequencing (WES and RNA-seq) and in vivo drug response testing, providing a robust and diverse dataset for evaluating biomarkers of response and non-response in prostate cancer drug development. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading Prostate Cancer PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Access to one of the largest  bank of prostate cancer PDX models with clinically relevant molecular
    and pathological characteristics on the market. 
  • Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
  • Includes models pretreated with advanced therapies like leuprolide, docetaxel, enzalutamide, bicalutamide and more.